We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03606486
Recruitment Status : Terminated (Terminated due to low accrual)
First Posted : July 30, 2018
Last Update Posted : January 20, 2023
Sponsor:
Collaborator:
Minnesota Ovarian Cancer Alliance
Information provided by (Responsible Party):
University of Washington

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this project is to develop a minimally invasive test to detect ovarian cancer, by searching for mutations from the tumor in samples obtained from the cervix (Pap smears), and from the uterus (uterine lavage) in women with advanced ovarian cancer. The investigators plan a pilot study of 25 women with advanced ovarian cancer. Pap smear and uterine lavage samples will be collected while the woman is under anesthesia for planned debulking surgery. A novel, highly sensitive and accurate technique, Crispr-Duplex sequencing, will be used to detect tumor associated mutations in TP53 (the most commonly mutated gene in ovarian cancer) within these samples. These results will be compared to sequencing results in the tumor itself for comparison, and Pap and uterine lavage will be compared to each other to determine the optimal test. Ultimately, the goal is to use the results of this study to plan a larger study including women without cancer who are at either increased risk or normal risk of ovarian cancer, for use in early detection.

Condition or disease Intervention/treatment Phase
High Grade Ovarian Serous Adenocarcinoma Stage III Ovarian Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Other: Biospecimen Collection Other: Laboratory Biomarker Analysis Device: Lavage Other: Pap Smear Not Applicable

Detailed Description:

OUTLINE:

Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas
Actual Study Start Date : November 16, 2018
Actual Primary Completion Date : December 9, 2022
Actual Study Completion Date : December 9, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Diagnostic (pap smear, uterine lavage, tumor sample)
Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
 Other: Biospecimen Collection
Undergo collection of tumor sample and blood draw

Other: Laboratory Biomarker Analysis
Correlative studies

Device: Lavage
Undergo uterine lavage
Other Name: Irrigation

Other: Pap Smear
Undergo pap smear
Other Names:
  • Cervical Smear Preparation
  • Cervical Smear Procedure
  • Pap Smear Procedure
  • Pap Test
  • Papanicolaou Smear Procedure
  • Papanicolaou Test
  • Vaginal Smears


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Sensitivity of pap smear versus sensitivity of uterine lavage in detection of tumor-derived TP53 mutations [ Time Frame: Up to 1 year ]
    Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.

  2. Specificity of pap smear versus specificity of uterine lavage in detection of tumor-derived TP53 mutations [ Time Frame: Up to 1 year ]
    Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • With suspected advanced ovarian cancer or genetic predisposition to malignant neoplasm of the ovary
  • Planned surgery
  • Have a uterus and no history of tubal occlusion

Exclusion Criteria:

  • Unable to speak English
  • Unable to provide informed consent
  • Prior hysterectomy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03606486


Locations
Layout table for location information
United States, Washington
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Sponsors and Collaborators
University of Washington
Minnesota Ovarian Cancer Alliance
Investigators
Layout table for investigator information
Principal Investigator: Barbara S. Norquist Fred Hutch/University of Washington Cancer Consortium
Principal Investigator: Rosana Risques Fred Hutch/University of Washington Cancer Consortium
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT03606486    
Other Study ID Numbers: 10019
NCI-2018-01242 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
RG1001786 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
First Posted: July 30, 2018    Key Record Dates
Last Update Posted: January 20, 2023
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Cystadenocarcinoma, Serous
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
 Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Genital Diseases
Endocrine System Diseases
Gonadal Disorders
Cystadenocarcinoma
Neoplasms, Cystic, Mucinous, and Serous